COLL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Collegium Reports Third Quarter 2026 Financial Results and Reaffirms Guidance

Nov 5, 2026

8-K

Collegium Pharmaceutical Resolves Nucynta Litigation and Terminates Grünenthal License Agreement

Oct 19, 2026

8-K

Collegium Pharmaceutical Announces $50 Million Accelerated Share Repurchase Agreement

Aug 13, 2026

8-K

Collegium Pharmaceutical Reports Q2 2026 Financial Results and Updates Full-Year Guidance

Aug 6, 2026

8-K/A

Corium Therapeutics Holdings, LLC Q1 2026 Financial Results and AZSTARYS Acquisition Update

Jun 30, 2026

8-K

Collegium Pharmaceutical, Inc. Announces Results of 2026 Annual Meeting of Shareholders

May 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Effect of Common Stock Change Event

Feb 11, 2020

424B5

Effect of Common Stock Change Event

Feb 10, 2020

424B5

Shares of our common stock having an aggregate offering price of up to $60,000,000.

Mar 13, 2017

424B5

5,000,000 Shares

Oct 27, 2016

424B5

200,000 shares reserved for future issuance under our 2015 Employee Stock Purchase Plan.

Oct 25, 2016

424B4

2,750,000 Shares

Jan 8, 2016

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 1, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 1, 2026

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jun 6, 2025

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jun 6, 2025

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jun 6, 2025

S-8 POS

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Jun 6, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 7, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 10, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 5, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 5, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

VANGUARD CAPITAL MANAGEMENT LLC (Filed by)

Oct 30, 2026

SCHEDULE 13G/A

PRINCIPAL GLOBAL INVESTORS (Filed by)

Oct 29, 2026

SCHEDULE 13G/A

INTEGRATED CORE STRATEGIES (US) LLC (Filed by)

Oct 8, 2026

144

Form 144 - Report of proposed sale of securities

Sep 30, 2026

SCHEDULE 13G

INTEGRATED CORE STRATEGIES (US) LLC (Filed by)

Aug 24, 2026

SCHEDULE 13G

FULLER & THALER ASSET MANAGEMENT, INC. (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 31, 2020

CORRESP

Form CORRESP - Correspondence

Mar 27, 2020

LETTER

Form UPLOAD - SEC-generated letter

Mar 23, 2020

LETTER

Form UPLOAD - SEC-generated letter

Mar 23, 2020

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 7, 2019

CORRESP

Form CORRESP - Correspondence

Nov 1, 2019

Collegium Pharmaceutical, Inc. COLL · SEC Filings